Mirati Therapeutics To Host Key Opinion Leader Breakfast On Immuno-oncology Combinations On July 11 In New York

SAN DIEGO, July 5, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology biotechnology company, announced today that they will host a Key Opinion Leader breakfast on the topic of Immuno-Oncology combinations on Tuesday, July 11 at 8:00am ET in New York City.

The meeting will feature presentations by key opinion leaders Jeffrey Weber, MD, PhD, (NYU, Perlmutter Cancer Center) and Matthew Hellmann, MD (Memorial Sloan Kettering Cancer Center) who will discuss the present and future landscape of immuno-oncology combinations in solid tumors, including recent advances presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. There will be a Q&A session immediately following the presentations.

Mirati Therapeutics' management team will also provide an overview of the Company's product pipeline, including their clinical-stage immuno-oncology programs that combine checkpoint inhibitors with their novel kinase inhibitor, sitravatinib, and their spectrum selective HDAC inhibitor, mocetinostat.

Dr. Jeffrey Weber is Professor of Medicine and the Deputy Director of the Laura and Isaac Perlmutter Cancer Center at the NYU-Langone Medical Center. A specialist in cancer immunotherapy, Dr. Weber is the principal investigator on numerous ongoing studies funded by the National Cancer Institute, and has held over a dozen INDs over the years in the field of immunotherapy. Dr. Weber's research interests are in the field of immunotherapy for cancer. As a translational clinical investigator, Dr. Weber has performed vaccine trials, protocols involving adoptive cell therapy, novel trials of checkpoint inhibition in melanoma patients and has been RO1 funded by the National Cancer Institute for over 20 years. His specific laboratory interests are in the monitoring and characterization of T cell responses in patients with cancer, and the establishment of in vitro models to facilitate the understanding of how immune modulation via abrogating and activating antibodies amplifies adaptive immunity in patients. He has been a pioneer in the clinical advancement of antibodies that block immune checkpoints in cancer, and the management of the autoimmune side effects resulting from that therapy. He has been a member of the NCI's Clinical Oncology Study Section and chair of the VA's Oncology Study Section. His prior experience includes positions at the University of Southern California where he was Chief of Medical Oncology and Associate Director for Clinical Research at the USC/Norris Comprehensive Cancer Center and being the PI of the SPORE in Cutaneous Oncology at the Moffitt Cancer Center where he was also the head of the Donald A. Adam Comprehensive Melanoma Research Center.

Matthew Hellmann, MD is a medical oncologist at Memorial Sloan Kettering Cancer Center, specializing in the care of patients with lung cancers, particularly non-small-cell lung cancers. Dr. Hellmann's research focuses on developing innovative and effective ways to harness the body's immune system to fight cancer. He is a member of the Immunotherapeutics Group, where they design lead early-phase clinical trials for immunotherapies for patients with a variety of different cancers. Dr. Hellmann is actively involved in several ongoing clinical trials for patients with NSCLC and metastatic solid tumors.

This event is intended for institutional investors, sell-side analysts, investment bankers, and business development professionals only. Please RSVP to Mac@LifeSciAdvisors.com in advance if you plan to attend, as space is limited.  For those who are unable to attend in person, a live webcast and replay will be accessible at http://lifesci.rampard.com/20170711/reg.jsp, and on the Investor Relations page of the company's corporate website at http://www.mirati.com/.

About Mirati Therapeutics

Mirati Therapeutics is a clinical-stage biotechnology company focused on developing a pipeline of targeted oncology products intended to treat specific genetic and epigenetic drivers of cancer. This approach is transforming the treatment of patients by targeting the genetic changes in tumor cells that result in uncontrolled tumor growth and migration. Our precision oncology programs seek to treat the patients most likely to benefit from targeted oncology treatments and are driven by drugs that target very specific genetic mutations, directed by genomic tests that identify patients who carry those driver mutations. Our immuno-oncology programs are novel small molecule drugs designed to enhance and expand the efficacy of checkpoint inhibitors when given in combination. In addition to our clinical programs, we have active discovery research efforts focused on novel oncology targets. The promise of these approaches includes potentially better patient outcomes, more efficient cancer treatment and faster drug development. For more information, visit www.mirati.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the business of the Company that are not historical facts may be considered "forward-looking statements," including, but not limited to, statements regarding Mirati's development plans and timelines, potential regulatory actions, expected use of cash resources, the timing and results of clinical trials, and the potential benefits of and markets for Mirati's product candidates.  Forward-looking statements are typically, but not always, identified by the use of words such as "may," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology.  Forward-looking statements are based on current expectations of management and upon what management believes to be reasonable assumptions based on information currently available to it, and are subject to risks and uncertainties.  Such risks and uncertainties may cause actual results to differ materially from the expectations set forth in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, potential delays in development timelines or negative clinical trial results, reliance on third parties for development efforts, changes in the competitive landscape, changes in the standard of care, as well as other risks detailed in Mirati's recent filings on Forms 10-K and 10-Q with the United States Securities and Exchange Commission. Mirati undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

SOURCE Mirati Therapeutics, Inc.